ENGINE BIOSCIENCES PTE.

We integrate machine learning, functional genomics, and drug discovery to enable and develop new and impactful precision medicines. Everything we do centers around patients: using specific genetic and treatment contexts to inform effective and well-tolerated therapeutics... Our approach and foundation were solidified by synthetic and computational biology pioneers at MIT, the Wyss Institute at Harvard, Mayo Clinic, UCSF, and UCSD. Our capabilities include: vast and curated knowledge and data bases on oncology gene interactions and synthetic lethality, proprietary combinatorial CRISPR screens, machine learning-based predictive algorithms extensively trained and iteratively enhanced by internal validation data, thorough validation across ranges of tools and models, drug discovery chemistry, and drug development... We are pleased to have garnered the support of leading, domain expert investors across US and Asia. Our investors include: Polaris Partners, ClavystBio (Life Sciences Venture..

Also known as: Engine Biosciences Pte. Ltd.

Primary location: Redwood City United States